The Food and Drug Administration (FDA) has granted Fast Track designation to ecopipam (Emalex Biosciences), an investigational agent for the treatment of Tourette syndrome (TS).
Phazix, a gel designed to help patients who have difficulty swallowing medications, has been made available over-the-counter by Arkray USA.
The FDA has rejected the supplemental New Drug Application for Hetlioz (tasimelteon; Vanda Pharmaceuticals) for the treatment of jet lag disorder.
Prescription drug use appears to be similar in the US and Canada, according to a new data brief from the Centers for Disease Control and Prevention (CDC).
Based on their findings, the authors concluded that further research is needed to better understand the long term effects of CAM therapy for depression.
Adjunctive treatment with pimavanserin did not result in a statistically significant change from baseline in Positive and Negative Syndrome Scale (PANSS) total score in patients with schizophrenia.
The FDA is looking to make the information in the Drug Abuse and Dependence section of product labeling more consistent and clear through a new draft guidance.
The use of cannabidiol (CBD), the non-intoxicating component of cannabis, has been associated with numerous adverse effects based on available evidence from animal and human studies.
Adhansia XR (methylphenidate HCl extended-release capsules) is expected to be available as of July 15, 2019 for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older, according to Adlon Therapeutics.
The Drug Enforcement Administration (DEA) has placed Zulresso (brexanolone; Sage Therapeutics), a treatment for postpartum depression, into Schedule IV of the Controlled Substances Act.
